Resolution of Medical Issues through Products and Services
Resolution of Medical Issues through Business Activities
Sysmex aims to provide advanced, high-value testing and diagnosis technologies. We have established an R&D vision, policies and promotion structure to foster innovation.
An R&D Structure That Generates Combinations of a Host of Technologies
The integration of different technologies employed in our instruments, reagents and software enables us to constantly incorporate voice of the customer into our product offerings. At Technopark, our hub for R&D, a congregation of researchers and engineers in a host of fields—electrical, mechanical, biological, chemical and IT, among others—encourages interaction and drives the creation and fusion of new technologies. We have built up a global R&D structure comprising R&D facilities in the United States, Germany, China and other countries.
In addition to expanding our own technology platforms, through open innovation we are pursuing collaboration with research institutes, universities and medical institutions in Japan and overseas. These efforts have led to the introduction of new candidates for diagnostic parameters and enable us to bring advanced and highly valuable diagnostic technologies and reagents to fruition more quickly.
Promoting the Joint Development of Groundbreaking Testing and Diagnostic Technologies through Open Innovation
In recent years, expectations have grown for personalized medicine, which provides healthcare optimized to individual patients. To realize personalized medicine, Sysmex Corporation is promoting joint R&D (open innovation) aimed at creating new value. To this end, we have established the Sysmex Open Innovation Lab (SOLA) within Technopark to encourage fusion between our own technologies and those of Japanese and overseas research institutions.
By inviting researchers from outside the Company to SOLA, we promote communication with our researchers and seek to foster a “fusion of knowledge.” We are also increasing collaboration with companies regardless of industry.
In one example, we are collaborating with JVCKENWOOD Corporation to determine at a detailed level the status of individual patient tissues and disease states by measuring exosomes (capsule-shaped particles) in the blood. Through these efforts, we are aiming for the joint development of groundbreaking testing and diagnostic technologies connected with the optimal administration of drugs. It is expected that the many substances exosomes contain might be employed as biomarkers* for diseases including cancer and central nervous system disorders. We are also involved in numerous other projects, ranging from those at the early research stages to projects nearing commercialization.
* Substances that act as markers for certain diseases
SOLA, a Place for Open Innovation
To accelerate R&D activities toward the realization of personalized medicine, in 2015 we opened the Sysmex Open Innovation Lab (SOLA) as a place for collaborative R&D with researchers outside the Company. Joint R&D is underway on our basic technology platforms: genes, cells, and proteins.
The Innovation Area, Replete with State-of-the-Art High-Performance Analyzers
The Communication Area, which encourages interaction among researchers, has spaces for free discussion and a book area to promote changes in perception.
The ICT Area provides supercomputer access and can be used for the analysis of medical big data.
Establishing a Joint Research Lab within the National Cancer Center Japan
Sysmex Cancer Innovation Laboratory（SCI-Lab）
In September 2013, Sysmex Corporation entered into a comprehensive collaboration agreement with the National Cancer Center Japan to develop diagnostic reagents for cancer. To date we have conducted joint research on 10 topics. In October 2015 we opened the Sysmex Cancer Innovation Laboratory (SCI-Lab) within the National Cancer Center Japan Hospital. This lab will further accelerate R&D in the field of cancer diagnosis with the aim of realizing genomic medicine*1. This lab meets ISO15189*2 international standards for clinical laboratories.
The SCI-Lab employs next-generation sequencers to conduct clinical research involving comprehensive genetic testing to measure around 100 gene types related to various types of cancer. This research is expected to contribute to decisions on appropriate treatment methods and use of drugs. This lab is operated in alliance with RIKEN GENESIS Co., Ltd., a Sysmex Group company with extensive experience in gene analysis.
We will continue to collaborate closely with the National Cancer Center Japan and RIKEN GENESIS, promoting research in the aim of realizing new cancer diagnosis methods as soon as possible.
*1 This type of medicine involves analyzing the relationship between genetic information and disease in order to predict the onset risk of diseases and aid in selecting the most effective course of treatment.
*2 This international standard specifies requirements for quality and competence in medical laboratories.
Development with the National Institute of Advanced Industrial Science and Technology of a Reagent to Test for Hepatic Fibrosis
Sysmex Corporation worked with the National Institute of Advanced Industrial Science and Technology (AIST) to develop the HISCL M2BPGi® Assay Kit, a reagent for testing for hepatic fibrosis through blood sampling alone. This was the world’s first practical application of technology employing a glycosylation marker* to test hepatic fibrosis.
Left untreated, viral hepatitis, one of Japan’s leading infectious diseases, can progress from chronic hepatitis and liver cirrhosis to hepatocellular carcinoma. To treat this disease, determining the degree of hepatic fibrosis due to the hepatitis virus is key. At present, the typical testing process involves living tissue diagnosis, or taking a biopsy of the liver tissue. This method requires hospitalization, placing a substantial burden on the patient on both the physical and economic fronts. The introduction of the HISCL M2BPGi® Assay Kit enables the rapid measurement of the progression of hepatic fibrosis solely through blood testing, reducing the burden on patients and contributing to testing efficiency.
In the aim of providing new reagents using glycosylation markers, in 2016 we also began working with AIST and GlycoBiomarker Leading Innovation Co. Ltd. (GL-i) on joint research into reagents as biomarkers for bile duct cancer.
* Sugar chains are linked monosaccharides that bind the surface of a cell or a protein in the blood. A glycosylation marker is a biomarker that targets structural changes in sugar chains arise from disease.
Sysmex Receives Merit Award from the Minister of Economy, Trade and Industry for the Practical Realization of a System for Diagnosing Hepatic Fibrosis Using Glycosylation Markers
In August 2016, Sysmex Corporation received the 14th Annual Merit Award from the Minister of Economy, Trade and Industry for Collaborative Achievement Between Industry, Academia and Government for the practical realization of a system for diagnosing hepatic fibrosis using glycosylation, developed in collaboration with Advanced Industrial Science and Technology (AIST).
The Annual Merit Award for Collaborative Achievement between Industry, Academia and Government was introduced in 2003 to recognize major success in industry–academia–government collaboration among companies, universities and public-sector research institutions successfully demonstrating examples of substantial contribution through leading-edge initiatives to help promote further industry–academia–government collaboration in Japan. The award received was one of 12 awards bestowed in the current Minister of Economy, Trade and Industry Awards, including the Prime Minister’s Award.
Overview of the 14th Annual Merit Award from the Minister of Economy, Trade and Industry for Collaborative Achievement Between Industry, Academia and Government
|Received for:||World’s first practical realization of a system for diagnosing hepatic fibrosis using glycosylation|
|Reason for award:||AIST has a global lead in glycosylation research, and collaboration with Sysmex has resulted in the world’s first commercialization of this research. This development enables the status of the entire liver (such as oncogenic risk) to be determined through blood testing only, enabling same-day testing (within 20 minutes) of chronic hepatitis patients.|
Contributing to the Early Detection and Treatment of Cancer
As of 2015, there were some 17.5 million cancer patients around the world, with deaths from cancer numbering an estimated 8.7 million. Between 2005 and 2015, the number of cases increased by 33%. Of this figure, 16.4% was attributable to society’s aging, 12.6% to population increases and 4.1% to changes in age-specific rates of cancer. Although varying widely by country and region, around the world it is said that one in three men and one in four women will contract cancer at some point in their lives, making cancer one of the most prevalent diseases*.
Through genetic testing and other technologies, Sysmex Corporation is working to contribute to the early detection and treatment of cancer, helping to improve the quality of life of individual patients.
* Source: Global Burden of Cancer 2015
Developing a Lab Assay Service for Research*1, with a View toward the Realization of Personalized Medicine
The Sysmex IMP lab, our base for lab assay services related to genetic testing
Sysmex Corporation has begun a lab assay service for research related to genetic testing.
In 2016, the Company began offering the Curebest® 95GC Breast assay service*2, which provides research data to predict recurrence by analyzing breast cancer tissue, and the number of institutions under contract and orders have been rising steadily. In addition, we are currently preparing to launch a lab assay service using BEAMing technology for detecting minute amounts of cancer-derived DNA in the blood.
Going forward, by providing assay services for research we aim to contribute to personalized medicine, which provides healthcare optimized to individual patients.
*1 Provision of laboratory testing results as services
*2 An analysis service for measuring the expression amounts of 95 genes related to breast cancer prognosis
The Spread of Testing Having a Low Physical and Economic Impact
Testing and treatment can place a substantial physical and economic burden on patients. In some cases, patients choose not to undergo testing and treatment for that reason. In others, they face the dilemma of undertaking treatment that comes at a reduced economic cost but carries a higher physical burden.
In an effort to change this situation, Sysmex is working to develop and popularize testing methods that have low physical and economic impact, so that more patients will undergo testing.
Strengthening Our Lineup of Urinalysis Products
UD-10 fully automated imaging unit for formed elements in urine (left)
UF-5000 fully automated analyzer of formed elements in urine (center)
UC-3500 fully automated urine chemistry analyzer (right)
Throughout the world, demand for urinalysis is increasing, as this type of testing provides a variety of physical information while placing a relatively small physical and economic burden on patients. In September 2015, Sysmex Corporation launched its UF-5000/4000/3000 fully automated analyzers of formed elements in urine. These instruments offer enhanced performance and an extended range of testing parameters, compared with conventional models. Furthermore, in January 2016 we introduced the UD-10 fully automated imaging unit for formed elements in urine. Through a business alliance with EIKEN CHEMICAL CO., LTD., we also began selling the UC-3500 fully automated urine chemistry analyzer (in overseas markets), the first under our own brand. These products, which employ the modular concept, can be combined with other instruments to meet diverse urinalysis needs.
Other Product and Service Topics (From Sysmex Corporation's News Releases in Fiscal 2016)
- Sysmex Receives CE Marking (European Conformity) for Liquid Biopsy RAS Testing for Metastatic Colorectal Cancer -Now Available for Clinical Practices-
- Sysmex’s Automated Blood Coagulation Analyzer Certified Under the 5th Heritage Program of Legacy Analytical Instruments/Scientific Instruments
- Sysmex, Astellas and Daiichi Sankyo Sign Memorandum of Understanding on the Creation of a Method for Analyzing Circulating Tumor Cells -Engaging in Joint Research to Create New Cancer Diagnostic Value and Applying It to Drug Research-
- Sysmex Enters into Research Collaboration Agreement in Relation to Cancer and Rare Diseases with the University of Tokyo -Aiming for the Clinical Application of Genomic Medicine-
- Cancer-Related Gene Panel Testing System Designated Under the Ministry of Health, Labour and Welfare’s Sakigake Designation System
- Medicaroid Launches the SOT-100 Vercia, Operating Table with the Function to Move Patients Widely